LDL-C lowering in patients treated with bempedoic acid in a real-world cohort.

ABSTRACT:

Background

Elevated low-density lipoprotein cholesterol (LDL-C) is directly associated with cardiovascular disease, with the risk level determined by the magnitude and duration of exposure. In routine practice, there are limited data on the expected LDL-C lowering with bempedoic acid (BA) alone or in combination with ezetimibe (BA + EZE).

Methods

Patients initiating BA or BA + EZE were identified in the Veradigm Network EHR linked to claims (index). LDL-C levels were evaluated at baseline, 3, 6, and 12 months. To further examine BA and BA + EZE efficacy, patients were stratified by background statin use (12 months pre-index) and by continuous index therapy use (no therapy gap >45 days).

Results

Of the 900 BA and 615 BA + EZE patients identified, median baseline LDL-C

SUBMITTER: Nelson J 

PROVIDER: S-EPMC12933831 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature